Schizophrenia

#FDA #Schizophrenia

FDA approves new drug for schizophrenia related agitation 

The Food and Drug Administration (FDA) has approved biopharmaceutical company BioXcel Therapeutics’ acute treatment for schizophrenia or bipolar disorder-associated agitation.   BioXcel Therapeutics’ IGALMI (dexmedetomidine) is the first new treatment for schizophrenia or bipolar disorder-associated agitation in almost 10 years, according to the company.  The FDA’s… Read More

#News

#Biosciences #Drug targets #Neuroscience #Schizophrenia

Collaboration to develop treatment for neuropsychiatric disorders 

Neurocrine Biosciences and Sosei Group Corporation have collaborated to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.  The agreement terms  Under the terms of the agreement, Neurocrine Biosciences gains development and commercialisation rights to… Read More

#News

Human brain
#Biomarkers #Clinical research #Schizophrenia #Therapeutics

Study to overcome biological heterogeneity challenges by 2022 

Monument Therapeutics, in collaboration with the University of Nottingham, has announced a preclinical study to support the use of their non-invasive biomarker for cognitive impairment in schizophrenia.  Currently, there are no treatments on the market for cognitive impairment associated with schizophrenia, despite efforts by pharmaceutical companies over… Read More

#News

#Collaboration #Drug development #Drug discovery #Gene mutation #Research #Schizophrenia

This week in drug discovery (13-17 September) 

News round-up by DDW’s Megan Thomas for 13-17 September  The news in the drug discovery industry this week has demonstrated the potential that remains untapped for a number of industries at large as well as taking early steps towards future cures and treatments. DDW’s Megan Thomas has… Read More

#News #Trending News

#Alzheimer's #Brain disease #Drug targets #Schizophrenia

Research reveals drug targets for memory enhancement  

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.  Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and… Read More

#News

#Collaboration #Drug discovery #Mass spectrometry / NMR #Parkinson's #Research #Schizophrenia #Therapeutics

This week in drug discovery (6-10 September) 

News round-up by DDW’s Megan Thomas for 6 – 10 September  DDW’s Megan Thomas selects five stories which showcase results, data, partnerships and research which offer a promising future for both drug development and eventual treatment of a number of diseases.   New potential therapy for… Read More

#News #Trending News

#Pharmaceuticals #Schizophrenia #Therapeutics

New potential therapy for schizophrenia patients

Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022.  Study 008A, a four-week, randomised, double-blind placebo-controlled international study, is designed to evaluate the efficacy, tolerability, and safety (including effects on the… Read More

#News

#Genetics #Neuroscience #Research study #Schizophrenia

Flies with schizophrenia genes respond well to anti-psychotics

Scientists have successfully treated flies displaying behavioural problems linked to newly discovered schizophrenia-associated genes in humans, using common anti-psychotics. Schizophrenia is a severe long-term mental health condition that is historically poorly understood and treated. It is relatively common, affecting 1-2% of the population, and is known to be up to… Read More

#News